中国生化药物杂志
中國生化藥物雜誌
중국생화약물잡지
CHINESE JOURNAL OF BIOCHEMICAL PHARMACEUTICS
2014年
2期
128-129,132
,共3页
吉西他滨%放射疗法%老年中晚期宫颈癌%不良反应
吉西他濱%放射療法%老年中晚期宮頸癌%不良反應
길서타빈%방사요법%노년중만기궁경암%불량반응
gemcitabine%radiation therapy%elderly advanced cervical cancer%adverse reaction
目的：探讨吉西他滨联合放疗治疗老年中晚期宫颈癌的近期临床疗效及不良反应。方法选择2009年6月～2012年2月河南科技大学第一附属医院新区医院收治的80例老年中晚期宫颈癌患者作为研究对象，将其随机均分为对照组与观察组，对照组（n=40）给予放疗，观察组（n=40）给予吉西他滨联合放疗，对比2组患者的临床疗效、不良反应发生率、生活质量等。结果治疗6周后2组总有效率均优于治疗1周后（P<0.05）；但2组间相比，总有效率差异无统计学意义。观察组患者生活质量评分显著高于对照组（P＜0.05），但观察组不良反应发生率亦显著高于对照组（P＜0.05）。结论采用吉西他滨联合放疗治疗老年中晚期宫颈癌，其临床疗效及患者近期生存质量较佳，但不良反应较大，临床可依患者具体情况选用。
目的：探討吉西他濱聯閤放療治療老年中晚期宮頸癌的近期臨床療效及不良反應。方法選擇2009年6月～2012年2月河南科技大學第一附屬醫院新區醫院收治的80例老年中晚期宮頸癌患者作為研究對象，將其隨機均分為對照組與觀察組，對照組（n=40）給予放療，觀察組（n=40）給予吉西他濱聯閤放療，對比2組患者的臨床療效、不良反應髮生率、生活質量等。結果治療6週後2組總有效率均優于治療1週後（P<0.05）；但2組間相比，總有效率差異無統計學意義。觀察組患者生活質量評分顯著高于對照組（P＜0.05），但觀察組不良反應髮生率亦顯著高于對照組（P＜0.05）。結論採用吉西他濱聯閤放療治療老年中晚期宮頸癌，其臨床療效及患者近期生存質量較佳，但不良反應較大，臨床可依患者具體情況選用。
목적：탐토길서타빈연합방료치료노년중만기궁경암적근기림상료효급불량반응。방법선택2009년6월～2012년2월하남과기대학제일부속의원신구의원수치적80례노년중만기궁경암환자작위연구대상，장기수궤균분위대조조여관찰조，대조조（n=40）급여방료，관찰조（n=40）급여길서타빈연합방료，대비2조환자적림상료효、불량반응발생솔、생활질량등。결과치료6주후2조총유효솔균우우치료1주후（P<0.05）；단2조간상비，총유효솔차이무통계학의의。관찰조환자생활질량평분현저고우대조조（P＜0.05），단관찰조불량반응발생솔역현저고우대조조（P＜0.05）。결론채용길서타빈연합방료치료노년중만기궁경암，기림상료효급환자근기생존질량교가，단불량반응교대，림상가의환자구체정황선용。
Objective To investigate the clinical efifcacy and adverse reactions of gemcitabine combined with radiotherapy in the treatment of elderly patients with advanced cervical cancer. Methods 80 elderly patients with advanced cervical cancer in the First Affiliated Hospital of Henan University of Science and Technology from June 2009 to Febrary 2012 were selected and randomly divided into control group(n=40) and observation group(n=40). Control group was given radiotherapy, while observation group was given gemcitabine combined with radiotherapy. The clinical efifcacy, incidences of adverse reactions and quality of life between two groups were compared. Results The total effective rates in 6 weeks after treatment were signiifcantly better than 1 week in both two groups(P<0.05), but there was no difference between two groups. The quality-of-life scores in observation group were signiifcantly higher than control group(P<0.05), but the incidence of adverse reactions in observation group was also signiifcantly higher than control group(P<0.05). Conclusion Gemcitabine combined with radiotherapy in the treatment of elderly patients with advanced cervical cancer has better clinical efifcacy and patients could enjoy a better quality of life, but it has a higher incidence of adverse reactions, so this combination therapy should depend on the speciifc situation of patients.
